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865-1 Endothelium-Derived Hyperpolarizing Factor Is Involved 
in Flow-Dependent Dilation of Peripheral Conduit 
Arteries in Healthy Volunteers
Dieter Fischer, Stephan Spiekermann, Ulf Landmesser, Marian Hospely, Smita 
Jategaonkar, Ingrid Fleming, Helmut Drexler, Burkhard Hornig, Medizinische Hochschule 
Hannover, Hannover, Germany, J.W. Goethe-Universität, Frankfurt, Germany
Background: Experimental data suggest that the endothelium-mediated, flow-depen-
dent vasodilation of peripheral arteries (FDD) is not only mediated by nitric oxide (NO)
but also by other relaxing factors, such as the cytochrome-p450-dependent endothelium-
derived hyperpolarization factor (EDHF). However, the contribution of EDHF for the
endothelium-mediated vasodilation of peripheral arteries in humans is unknown.
Methods: FDD of the radial artery was determined in 12 healthy volunteers by high reso-
lution ultrasound. To inhibit vascular cyclooxygenase dependent vasodilation, we injected
500 mg acetylsalecyl acid 30 min before FDD-measurements. FDD was analyzed during
control conditions and after intra-arterial infusion (5 min) of sulfaphenazole, a specific
inhibitor of the isoenzyme 2C9 of the cytochrome-p450(4 mg/min), following L-NMMA
(NO-synthase-inhibitor, 7 µmol/min) and after co-infusion of both, each 5 min. Further-
more, endothelium-independent vasodilation was characterized after intra-arterial infu-
sion of SNP (9 µg/min, 5 min).
Results: FDD at baseline was 11.5±3%, following sulfaphenazole 7.4±3.3% (p<0.01 vs.
control), after L-NMMA 6.0±2.4% (<0.01 vs. control), after co-infusion of L-NMMA and
sulfaphenazole 3.9±2.5% (p<0.01 vs. control, p<0.05 vs. L-NMMA, p<0.01 vs. sul-
faphenazole). Sulfaphenazole had no effect on endothelium-independent vasodilation
(SNP: 19.6±6.2%, SNP+sulfaphenazole:20.2±6.8, p=n.s.).
Conclusion: FDD of the radial artery was substantially reduced In healthy volunteers
after inhibition of cytochrome-p450 2C9 or NO-synthase. Co-infusions of both inhibitors
for NO-synthase and EDHF had incremental inhibitory effects on FDD. Thus, our results
support the concept that EDHF contributes to flow-dependent dilation of peripheral con-
duit arteries in normal human volunteers in vivo.
8:45 a.m.
865-2 1166 A/C Polymorphism of the Angiotensin AT1 
Receptor Gene Alters Simvastatin-Induced Change in 
the Endothelial Function
Marek Kiliszek, Michal Maczewski, Beata Burzynska, Grzegorz Styczynski, Monika 
Duda, Andrzej Beresewicz, Grzegorz Opolski, Medical University of Warsaw, Warsaw, 
Poland, Medical Centre of Postgraduate Education, Warsaw, Poland
Background: Angiotensin AT1 receptors (AT1R) may influence function of vascular
endothelium via stimulation of free radicals production. We examined relationship
between 1166A/C polymorphism of the AT1R gene and statin related changes in endot-
helial function and AT1R density.
Methods: In 17 pts with coronary artery disease (not on hypolipemic treatment) lipid pro-
file, platelet AT1R density and endothelial function (brachial artery flow mediated dilation
FMD, NO metabolites: nitrate&nitrite concentration) were performed at baseline and after
treatment with simvastatin 40mg/24h for 12 weeks. All subjects were genotyped for the
1166A/C polymorphism.
Results: At baseline there were no differences between pts carrying AA allele (n=9) vs.
C allele (AC and CC; n=8) in LDL cholesterol, AT1R density and FMD. Pts carrying AA
allele had at baseline lower nitrate&nitrite concentration (13,84±4,43 vs. 21,39±9,45uM;
p=0,048). After simvastatin AA pts had significant improvement in endothelial function
while AC or CC pts had no improvement in endothelial function (table). There were no dif-
ferences between AA homozygotes and all C allele carriers in simvastatin-induced reduc-
tion in LDL cholesterol and AT1R density.
Conclusions: Influence of statin on endothelial function is modulated by 1166A/C poly-
morphism of the angiotensin AT1R gene. This polymorphism does not affect (i) the base-
line AT1R density and baseline LDL (ii) simvastatin induced reduction of LDL and AT1R
density.
Table: 
9:00 a.m.
865-3 Improvement of Endothelium-Dependent Vasodilation 
by Simvastatin Is Potentiated by Combination With L-
Arginine in Patients With Elevated Asymmetric 
Dimethylarginine Levels
Gerhild I. Boger, Renke Maas, Edzard Schwedhelm, Anneke Bierend, Ralf Benndorf, 
Mariola Kastner, Anna Steenpaß, Rainer H. Boger, University Hospital Hamburg-
Eppendorf, Hamburg, Germany
Background. Statins stimulate the expression of endothelial NO synthase (eNOS) in vitro
and enhance endothelium-dependent, NO-mediated vasodilation in vivo. Asymmetrical
dimethylarginine (ADMA) is an endogenous, competitive inhibitor of eNOS. The presence
of elevated plasma ADMA levels is associated with endothelial dysfunction. We investi-
gated the hypothesis that simvastatin may enhance endothelial function in patients with
elevated ADMA only if the inhibitory effect of ADMA is overcome by supplemental L-argi-
nine.
Methods. 15 clinically asymptomatic, elderly subjects with elevated ADMA levels
received, in a randomised order, simvastatin (40 mg/day), L-arginine sustained-release
(3 g/day), or a combination of both, each for 3 weeks, in a three period crossover design
with at least three weeks of wash-out between treatments. Endothelium-dependent
vasodilation was assessed by brachial artery ultrasound using computer-assisted image
analysis; ADMA and L-arginine plasma concentrations were determined by a validated
HPLC method.
Results. Analysis of 12 subjects who completed the study revealed that simvastatin had
no effect on endothelium-dependent vasodilation when administered alone (6.2±1.2% vs.
6.1±0.9%). L-arginine significantly improved endothelial function (8.7±0.7 vs. 4.9±0.8%;
p<0.02). When given in combination with L-arginine, simvastatin had a significant benefi-
cial effect on endothelial function (9.8±1.5 vs. 5.3±0.8%; p<0.01). Endothelium-indepen-
dent vasodilation by glyceryl trinitrate was not affected by any of the treatments.L-
arginine, either alone or in combination with simvastatin, significantly improved plasma L-
arginine/ADMA ratio (baseline, 82.3±4.0 vs. 102.8±9.2 and 102.6±10.8, respectively,
each p<0.05).
Conclusions. Simvastatin does not enhance endothelial function in subjects in whom
eNOS is blocked by elevated ADMA levels; combination of simvastatin with oral L-argin-
ine has a synergistic effect on endothelial function. As NO-mediated effects may play a
major role in therapeutic effects of statins, combination with L-arginine should be consid-
ered in patients with elevated ADMA concentration.
9:15 a.m.
865-4 Tetrahydrobiopterin Prevents Vascular Injury After 
Ischemia-Reperfusion in Humans
Vasilis C. Babaliaros, Arshed A. Quyyumi, Uma P. Reddy, W. Lance Lewis, Sonya L. 
Lefever, W. Robert Taylor, Emory University School of Medicine, Atlanta, GA
BACKGROUND: Vascular inflammation and subsequent endothelial dysfunction are piv-
otal steps in the initiation of ischemia-reperfusion injury. Ischemic preconditioning is well
known to have protective effects although the mechanism through which it occurs
remains incompletely understood. We hypothesized that tetrahydrobiopterin (BH4) plays
a critical role in ischemic preconditioning, and its administration prevents reperfusion
injury. METHODS: Baseline endothelial function of the radial artery was measured in 21
healthy volunteers (mean age 36.2±2.9 years) using flow-mediated dilation (FMD). Sub-
jects were divided into 3 groups: A) arm ischemia induced by a 20 minute cuff inflation B)
preconditioning with three 5-minute cuff inflations followed by 20 minute cuff inflation and
C) administration of BH4 (500µg/min) into the brachial artery followed by 20 minute cuff
inflation. FMD was measured in all groups after 15 minutes of reperfusion. RESULTS:
Twenty minutes of cuff inflation followed by reperfusion induced ischemic vascular injury
as evidenced by impaired FMD (pre 7.4±0.6%, post -0.5 ±0.9%, p<0.001). In addition,
ischemic preconditioning preserved endothelial function (FMD pre 6.8±0.6%, FMD post
7.4±1.0%, p=0.6, NS). Importantly, administration of BH4 also reduced the development
of endothelial dysfunction (FMD pre 7.32±0.8%, FMD post 4.8±0.7%, p=0.03; p=0.002
compared with post-FMD of the ischemia-reperfusion group). CONCLUSIONS:
Ischemia-reperfusion produces significant endothelial dysfunction in humans that can be
prevented by ischemic preconditioning. Reperfusion injury is also dramatically attenuated
by the administration of BH4. These findings suggest that reperfusion vascular injury
occurs secondary to BH4 depletion and the uncoupling of eNOS.
9:30 a.m.
865-5 Six Months of Weight Loss Improves Metabolic and 
Vascular Indices in Overweight Adults
Thomas P. Olson, Aaron S. Kelly, Alan J. Bank, Daniel R. Kaiser, Donald R. Dengel, 
University of Minnesota, Minneapolis, MN, St. Paul Heart Clinic, St. Paul, MN
Background: Obesity is a risk factor for cardiovascular disease and is characterized by
metabolic and vascular abnormalities.We examined the effects of weight loss on meta-
bolic and cardiovascular parameters. Methods: Twelve (F=9, M=3) overweight (BMI
30.3±3.7) adults (54.9±3.9 yr) without diabetes or vascular disease were counseled by a
registered dietician to lose weight over six months. Vascular structure, function, and wall
mechanical properties were measured via ultrasound. Insulin sensitivity (IVGTT), body
composition (dual-energy x-ray absorptiometry), and lipids were also assessed. Results:
There were significant reductions in body mass (86.3±14.2 vs. 79.5±13.8 kg, p<0.0001)
and percent fat (44.3±7.0 vs. 41.0±8.5%, p<0.01) after weight loss. There were signifi-
cant improvements in total cholesterol (230.9±33.9 vs. 194.8±30.7 mg/dl, p<0.0001),
LDL-C (149.3±27.2 vs. 123.7±24.0 mg/dl, p<0.0001), triglycerides (131±88.6 vs.
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FMD (%) 8,27(2,30) 11,25(2,79) 0,012 10,15(7,86) 9,26(4,68) 0,65
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